|
Evaluation of the Prognostic Role of Survivin and Maspin in Breast
Cancer Patients: A Clinicopathologic and Immunohistochemical Study
Mohamed M. Shareef 1, Mona A. Abd-El-Azeem 1,
Hanan S. Mahmoud 2 and Tamer A. El-Bakary 3
Departments of Pathology 1, Clinical Oncology 2
and General Surgery 3, Faculty of Medicine, Tanta
University, Egypt
Tanta Med. Sc. J 2009; 4(3):119-131
ICID: 913698
Article type: Original articleIC™ Value: 4.54
| Abstract provided by Publisher |
 |
Background/Aim: Breast cancer is the most common malignancy and the
second most common cause of cancer death in females. So, there is a
continuous need for the development and search for new prognostic
markers which will aid in therapy. Survivin is an important
inhibitor of apoptosis that is over-expressed in many human cancers,
including breast, but not expressed in normal tissue. It has been
suggested that the expression of this protein may be associated with
a more aggressive behavior and decreased survival in various
malignancies. Maspin is a member of the serine protease inhibitor
family, which is claimed to have a tumor-suppressive activity.
Contradictory data have been reported in the literature concerning
the role and the prognostic impact of both markers in breast cancer.
The aim of this work is to study the expression of survivin and
maspin in breast invasive ductal carcinoma and to correlate these
data with clinicopathologic findings and patient survival to assess
their prognostic significance. Patients & Methods: Paraffin blocks
obtained from 61 female patients with non-metastatic invasive breast
ductal carcinomas were analyzed for maspin and survivin
immunohistochemical expression. Results: Survivin showed positivity
in 39 cases (64%). There was a significant correlation with HER-2
status, disease free survival [DFS] (both with p=.001), tumor size,
nodal status and grade (all p <.001) and inverse correlation with ER
status (p<.001). Maspin showed positivity in 20 cases (33%). There
was a statistical correlation with the ER status and all the studied
clinicopathologic features except the age of the patients. There
were also positive correlations between maspin and survivin
expression. Conclusion: survivin and maspin appear to be potentially
useful markers of bad prognosis in breast cancer and can be used to
detect cases with aggressive biological behavior that can benefit
from aggressive therapy.
ICID 913698
|